Navigation Links
Cancer Mortality Increases With Cancer Cell Replikin Count
Date:12/4/2008

Drs. Samuel and Elenore Bogoch of Oncolab, Inc. have found that the concentration of replikins, a new class of peptides in genomic proteins*, are quantitatively related to the mortality rate in human cancer of different cell types. No cancer cell genomic structure has previously been reported to be quantitatively related to mortality rate.

Boston, MA (PRWEB) December 4, 2008 -- Drs. Samuel and Elenore Bogoch of Oncolab, Inc. have found that the concentration of replikins, a new class of peptides in genomic proteins*, are quantitatively related to the mortality rate in human cancer of different cell types. No cancer cell genomic structure has previously been reported to be quantitatively related to mortality rate.


     
The attached figure shows the relationship between the Replikin Count™ in the Replikin Peak Gene* and the percent mortality in human cancer: the higher the Replikin Count, the higher the percent mortality after 5 years.  Glioblastoma multiforme and non-small-cell lung cancer, the two cancer cell types with the greatest 5-year mortality rates in 2002 (98% and 91% respectively), are also the cell types which have the highest Replikin Counts (325 and 250 respectively).
 
The count in Glioblastoma Multiforme is 18 times higher than the counts in prostate and thyroid cancer which have the lowest Replikin Counts (20 and 15 respectively) as well as the lowest 5-year mortality rates (each approximately 2%). The quantitative relationship of Replikin count to mortality is also seen in the figure for other common cancers, which shows some deviations from an 'ideal' curve. For example, gastric cancer has a higher mortality rate than expected from its Replikin Count (ie shifted to the right), possibly because of the known difficulty of early detection of gastric cancer. Breast and urinary bladder cancer have lower mortality rates than expected from their Replikin Counts (ie shifted to the left), possibly because of the improvement in their early detection and prompt treatment.
 
To obtain these results, all cancer protein sequences published on PubMed were analyzed by histological cancer cell type by ReplikinForecast™ software. The Replikin Peak Gene (RPGene)* was identified in each cell type. The replikins in each RPGene were counted (Replikin Count = number of replikins per 100 amino acids).  The Replikin count of each RPGene then was compared in the different histological cancer cell types as shown in the attached Figure.
 
Replikin count has already been shown by Replikins, Ltd. to be related to rapid replication, disease outbreaks, and host mortality in viruses such as influenza and HIV, bacteria, malaria, and other infectious diseases*. The relationship between Replikin count and mortality in cancer parallels that found in H5N1 virus in humans and in Taura Syndrome Virus in shrimp.
 
The authors speculate that in low mortality cancers, it is possible that the immune system may be adequate to the number of invading units; but that the increased mortality rate in viruses and in cancer may reflect the overwhelming of host immune defenses by markedly increased numbers of viruses or of cancer cells produced in each case by increasing replikin concentration in the up-regulated Replikin Peak Gene.  An increase in number of cancer cells per unit time produced by rapid replication has been demonstrated in the laboratory in the case of glioblastoma multiforme brain cancer cells in tissue culture*. The quantitative relationship of Replikin Count to mortality rate has been demonstrated in the laboratory in four strains of lethal Taura Syndrome Virus in shrimp*.
 
These findings have diagnostic, therapeutic, and preventive applications. On the diagnostic side, 1) Oncolab, Inc.'s AMAS®Test, FDA permitted to market and Medicare approved, measures an anti-replikin antibody called the antimalignin antibody useful in the early detection of cancer. 2) Oncolab is now developing a test to determine the lethality of cancer specimens with the use of ReplikinsForecast™ to analyze the replikins in cancer cell protein sequences.  Encouraged by the proof of principle demonstration that synthetic replikin vaccines can be effective (91% of shrimp who received an oral synthetic replikin vaccine survived lethal Taura Syndrome virus challenge), synthetic replikin cancer vaccines are currently in development.
 
 
*References:
 
For published detailed antimalignin antibody data by Oncolab,Inc. and the replikins data of Replikins Ltd. studies,  see www.uspto.gov. For summaries see replikins.com under "Replikins Press" and OncolabInc.com.  Contacts: Oncolab, Inc. 617-536-9711; Replikins, Ltd. 617-536-0220.

# # #

Read the full story at http://www.prweb.com/releases/cancer/replikins/prweb1705354.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Molecular Breast Imaging Outperforms MRI for Patients With Inconclusive Results in the Diagnosis of Cancer
2. Molecular Breast Imaging Identifies Occult Cancer
3. Medicsight PLC Presents New Data at RSNA 2008 Further Supporting Relevance of Computer-Aided Detection (CAD) and Image Analysis Software in Early Colon Cancer Screening and Diagnosis
4. Prostate Cancer Stimulates Nerve Growth
5. Researchers discover new enzyme in cancer growth
6. International study supports new standard of treatment for women with advanced ovarian cancer
7. Genetic breakdown in Fanconi anemia may have link to HPV-associated cancer
8. Broccoli compound targets key enzyme in late-stage cancer
9. Prostate cancer drug reduces testosterone levels in as little as 3 days
10. More High-Risk Women Preempt Breast Cancer
11. New breast imaging technology targets hard-to-detect cancers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cancer Mortality Increases With Cancer Cell Replikin Count
(Date:5/4/2016)... ... May 04, 2016 , ... May kicked off with Melanoma ... United States. Dermatologist Dr. Ellen Turner is encouraging her patients, as well as residents ... on skin safety and health now and in the future. , The dermatology-specific awareness ...
(Date:5/4/2016)... , ... May 04, 2016 , ... ... is transforming breastfeeding for nursing mothers. The company’s patented technology, The Smart Breastfeeding ... Today, the company announced that the technology is now available for purchase at ...
(Date:5/4/2016)... ... 2016 , ... Francesca Loparco, Co-Founder of Queen City Dream Cars, an exotic ... LASIK procedure at Christenbury Eye Center. The entrepreneur struggled with her computer, riding ... same day as her in-office consultation and eye exam. Francesca’s eyesight was restored to ...
(Date:5/4/2016)... ... May 04, 2016 , ... The preeminent surgical aftercare facility Pearl Recovery Retreat ... cancer surgery. In March 2016, the 61-year-old model and reality TV star was diagnosed ... in the milk ducts, according to an interview with the Daily Mail Online ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... billing and compliance. In upcoming months, AudioEducator has lined up some informative training ... is designed to give complete compliance know-how and practical, easy-to-apply advice. , On ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... Mo. , May 3, 2016 ... Medical Center,s Institute for Advancing Medical Innovation (IAMI) ... commercialize new drugs, diagnostics and medical devices. ... BioNovus Innovations with rights to license, develop and ... "This partnership represents a ...
(Date:5/3/2016)... -- ACME Markets, Delaware County ... Delaware County Councilman Dave White announced today ... ACME pharmacies across Delaware County ... (CDC), naloxone has saved 26,463 lives nationwide over the past 20 ... County were authorized to administer naloxone to overdose victims, ...
(Date:5/3/2016)... , May 3, 2016   Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is ... a video of two patients who tell their personal story and encourage those at risk ... Meet Jacque: Hepatitis C ... ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ...
Breaking Medicine Technology: